Key Points Summary
- Tirzepatide is a dual-action medication that mimics two natural hormones (GIP and GLP-1) to regulate blood sugar and appetite
- Mounjaro is the brand name approved for type 2 diabetes treatment, while Zepbound is specifically approved for chronic weight management
- Clinical trials show patients can lose 15-20% of their body weight on average over 72 weeks
- The medication is administered as a once-weekly injection with gradually increasing doses
- Common side effects include nausea, diarrhea, and digestive discomfort, especially when starting treatment
- Tirzepatide is only available by prescription and requires medical supervision